Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.84 |
| ▸ | FGFR2 | P21802 | 14/20 | 0.84 |
| ▸ | FGFR4 | P22455 | 14/20 | 0.84 |
| ▸ | FGFR3 | P22607 | 14/20 | 0.84 |
| ▸ | KDR | P35968 | 13/20 | 0.84 |
| ▸ | FLT1 | P17948 | 11/20 | 0.84 |
| ▸ | FLT4 | P35916 | 11/20 | 0.84 |
| ▸ | SRC | P12931 | 2/20 | 0.79 |
| ▸ | GLA | P06280 | 1/20 | 0.79 |
| ▸ | CSK | P41240 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | ATM | Q13315 | 1/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30737861 | 0.91 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL22532273 | 0.91 | FGFR1 (0.82) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL19601461 | 0.91 | FGFR1 (0.88) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL19848922 | 0.89 | FGFR1 (0.80) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15047127 | 0.89 | FGFR1 (0.80) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2470675 | 0.89 | FGFR1 (0.85) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL24490071 | 0.88 | FGFR1 (0.79) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL29390591 | 0.88 | FGFR1 (0.79) | FGFR1FGFR2FGFR4FGFR3KDR | |
| Pd-173074 SCHEMBL29828472 | 0.88 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| Pd-173074 SCHEMBL177946 | 0.88 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113747894-B | Degradation agents for fibroblast growth factor receptor 2 (FGFR 2) | 丹娜-法伯癌症研究公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20220175722-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220175722-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3952863-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | Dana-Farber Cancer Institute, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020210451-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7037912-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050261318-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-11-24 | — | — | US | disclosed |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-11-25 | — | — | US | disclosed |
| US-6750241-B2 | Protein kinase inhibitors | THERAVANCE, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020177600-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-11-28 | — | — | US | disclosed |
| US-20020002169-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-01-03 | — | — | US | disclosed |
| WO-2001042243-A2 | PROTEIN KINASE INHIBITORS | ADVANCED MEDICINE, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175722-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | FGFR2, FGF2, FGFR1 | FGFR1 3/4885FGFR2 1/4885FGFR4 6/4885 |
| US-20020177600-A1 | Protein kinase inhibitors | MAP3K20, MAP3K9, MAP3K6 | FGFR1 797/4885FGFR2 1381/4885FGFR4 2414/4885 |
| US-20020002169-A1 | Protein kinase inhibitors | MAP3K20, MAP3K6, MAP4K2 | FGFR1 848/4885FGFR2 1173/4885FGFR4 1995/4885 |
| US-20050261318-A1 | Protein kinase inhibitors | MAP3K20, MAP3K6, MAP4K2 | FGFR1 848/4885FGFR2 1173/4885FGFR4 1995/4885 |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | UACA, PRKDC, CDK2 | FGFR1 739/4885FGFR2 1138/4885FGFR4 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.